Seizure: European Journal of Epilepsy
Volume 19, Issue 3 , Pages 195-197 , April 2010

Long-term efficacy of valproate versus lamotrigine in treatment of idiopathic generalized epilepsies in children and adolescents

Received 11 October 2009 ,Revised 19 January 2010 ,Accepted 22 January 2010.

References 

  1. Nicolson A, Appleton RE, Chadwick DW, Smith DF. The relationship between treatment with valproate, lamotrigine, and topiramate and the prognosis of the idiopathic generalized epilepsies. J Neurol Neurosurg Psychiatry. 2004;75:75–79
  2. Bergey GK. Evidence-based treatment of idiopathic generalized epilepsies with new anti-epileptic drugs. Epilepsia. 2005;46(Suppl 9):161–168
  3. Marson AG, Al-Kharusi AM, Alwaidh M, Appleton R, Baker GA, Chadwick DW, et al. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalized and unclassifiable epilepsy: an unblinded randomized controlled trial. Lancet. 2007;369:1016–1026
  4. Wirrell EC. Valproic acid-associated weight gain in older children and teens with epilepsy. Pediatr Neurol. 2003;28:126–129
  5. Diav-Citrin O, Shechtman S, Bar-Oz B, Cantrell D, Arnon J, Ornoy A. Pregnancy outcome after in utero exposure to valproate: evidence of dose relationship in teratogenic effect. CNS Drugs. 2008;22:325–334
  6. Wyszynski DF, Nambisan M, Surve T, Alsdorf RM, Smith CR, Holmes LB. Increased rate of major malformations in offspring exposed to valproate during pregnancy. Neurology. 2005;64:961–965
  7. Vajda FJ, O’Brien TJ, Hitchcock A, Graham J, Cook M, Lander C, et al. Critical relationship between sodium valproate dose and human teratogenicity: Results of the Australian register of anti-epileptic drugs in pregnancy. J Clin Neurosci. 2004;11:854–858
  8. Vajda FJ, O’Brien TJ, Hitchcock A, Graham J, Lander C. The Australian registry of anti-epileptic drugs in pregnancy: experience after 30 months. J Clin Neurosci. 2003;10:543–549
  9. Morris GL, Hammer AE, Kustra RP, Messenheimer JA. Lamotrigine for patients with juvenile myoclonic epilepsy following prior treatment with valproate: results of an open-label study. Epilepsy Behav. 2004;5:509–512
  10. Buchanan N. The use of lamotrigine in juvenile myoclonic epilepsy. Seizure. 1996;5:149–151
  11. Messenheimer J. Efficacy and safety of lamotrigine in pediatric patients. J Child Neurol. 2002;17(Suppl 2):2S34–32S42
  12. Frank LM, Enlow T, Holmes GL, Manasco P, Concannon S, Chen C, et al. Lamictal (lamotrigine) monotherapy for typical absence seizures in children. Epilepsia. 1999;40:973–979
  13. Valencia I, Pinol-Ripoll G, Khurana DS, Hardison HH, Kothare SV, Melvin JJ, et al. Efficacy and safety of lamotrigine monotherapy in children and adolescents with epilepsy. Eur J Paediatr Neurol. 2009;13:141–145
  14. Curatolo P, Moavero R, Lo Castro A, Cerminara C. Pharmacotherapy of idiopathic generalized epilepsies. Expert Opin Pharmacother. 2009;10:5–17
  15. Rambeck B, Wolf P. Lamotrigine clinical pharmacokinetics. Clin Pharmacokinetics. 1993;25:433–443
  16. Carpay HA, Arts WF, Geerts AT, Stroink H, Brouwer OF, Boudewyn Peters AC, et al. Epilepsy in childhood: an audit of clinical practice. Arch Neurol. 1998;55:668–673
  17. Montouris G, Abou-Khalil B. The first line of therapy in a girl with juvenile myoclonic epilepsy: should it be valproate or a new agent?. Epilepsia. 2009;50(Suppl 8):16–20

PII: S1059-1311(10)00015-4

doi: 10.1016/j.seizure.2010.01.014

Seizure: European Journal of Epilepsy
Volume 19, Issue 3 , Pages 195-197 , April 2010

Article Tools

* Image Usage & Resolution